読み込み中
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
前日終値
$2.25
+$0.43 · +23.63%
日中の時刻はETです。市場データは遅延する場合があります。
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
日中レンジ
現在 $2.25
52週レンジ
現在 $2.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
33
割高
センチメント
31
弱気
リスク
67
高リスク
モメンタム
36
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
日中レンジ
現在 $2.25
52週レンジ
現在 $2.25
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 646.5万 USD | 635.3万 USD | 570.5万 USD | — | 284.2万 USD |
| 粗利益 | −646.5万 USD | −635.3万 USD | −570.5万 USD | — | −284.2万 USD |
| 研究開発 | 4111万 USD | 5047.7万 USD | 4725.1万 USD | 3767.2万 USD | 2651万 USD |
| 販売・一般管理 | 2572.7万 USD | 3099.9万 USD | 2890.1万 USD | 2594.6万 USD | 2114.6万 USD |
| 営業費用 | 6037.2万 USD | 7512.3万 USD | 7044.7万 USD | 6361.8万 USD | 4765.6万 USD |
| 受取利息 | 786.8万 USD | 1078万 USD | 1255万 USD | 581.6万 USD | 32.9万 USD |
| 減価償却費と償却費 | 646.5万 USD | 635.3万 USD | 570.5万 USD | 341.6万 USD | 284.2万 USD |
| 営業利益 | −6683.7万 USD | −8147.6万 USD | −7615.2万 USD | −6361.8万 USD | −5049.8万 USD |
| 純利益 | −5900.1万 USD | −7078万 USD | −6367.5万 USD | −5792.4万 USD | −5031.5万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$3.50
上昇余地（55.56%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM248.19万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI187.73万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF52.83万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC34.2万0.03%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 ETFVTWO27.91万0.00%180億 USD0.06%$112.66+0.50%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17万0.14%1.17億 USD0.73%$15.9402+0.25%
iShares Russell 2000 Growth ETFIWO12.16万0.00%139.17億 USD0.24%$356.78+0.94%
Global X - Russell 2000 ETFRSSL5.39万—14.19億 USD0.08%$109.09+0.21%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMiShares Russell 2000 Growth ETFIWOGlobal X - Russell 2000 ETFRSSLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
